Bob More

Bob More brings over 20 years of life sciences investing experience.

Bob currently serves on the board of Kelonia Therapeutics, MBrace Therapeutics, Tyra Biosciences (NASDAQ: TYRA), Variant Bio, and Vir Biotechnology, Inc (NASDAQ: VIR). He also manages the investment in eGenesis. He was a founding board member of the Kauffman Fellows Program and previously served on the board of BIO (Biotechnology Innovation Organization).

Prior to Alta, Bob was a Senior Advisor for the Bill and Melinda Gates Foundation. Prior to that, Bob spent 5 years as a General Partner at Frazier Healthcare Ventures and 13 years at Domain Associates. Bob managed successful investments in and served on the boards of Affinivax (acquired by GSK), Cartiva (acquired by Wright Medical), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Glaukos Corporation (NYSE: GKOS), IntraLase (acquired by Advanced Medical Optics), Neothetics (merged with Evofem), NovaCardia (acquired by Merck), Oceana Therapeutics (acquired by Salix Pharmaceuticals) and Proxima Therapeutics (acquired by Cytyc Corporation). Bob was also an investor in Clovis Oncology (NASDAQ: CLVS), Encoded Genomics and Zeltiq Aesthetics (acquired by Allergan).

He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.